SatNav for Oncology Developers May Help Celleron Steer AZ's HDAC Inhibitor
This article was originally published in Start Up
Executive Summary
Ever get lost? Get one of the many satellite navigation systems for your car or even your phone. But what happens when oncology drug developers are hitting dead ends in the clinic, even with the most promising cancer candidates? Celleron Therapeutics may have just the technology to put drugs on the right path-and now it has a high-profile clinical compound to drive through the clinic. In May 2009 the biotech landed worldwide rights to AstraZeneca's lead histone deacetylase (HDAC) inhibitor, AZD9468, adding to the list of pharmaceutical players who have opted, for now, to exit the promising but tricky HDAC space.